Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought
Novo Nordisk's GLP-1 franchise is advancing strongly and will be reinforced later this year by the expected approval of the ground-breaking oral semaglutide diabetes therapy, said CEO Lars Fruergaard Jørgensen
You may also be interested in...
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.